Crohn’s disease(CD) is defined as a lifelong chronic relapsing and remitting gastrointestinal condition, with inflammation of the gastrointestinal tract. The condition is defined by abdominal pain, diarrhea and fatigue and incidences of Chrohn’s disease occur in 10 cases per 100,000 population per year.
Supplementation with vitamin D may impact on the intestinal barrier associated with Chrohn’s disease and lowers the intestinal barrier dysfunction. The research participants consisted of 27 patients in remission who took part in a double-blind randomized placebo-controlled study with a 2000 IU/day vitamin D supplementation or placebo for 3 months.
The findings determined that patients who consumed vitamin D supplementation were more likely to maintain their intestinal permeability, whereas this deteriorated in the placebo group.
“This is the first reporting of effects of vitamin D supplementation on intestinal permeability and antimicrobial peptide measures in a CD cohort. Whilst the data requires further confirmation, it broadly supports evidence from previous experimental studies that suggest a role for vitamin D in maintaining intestinal barrier integrity.”
“This is an exciting development in the treatment of Crohn’s disease and we welcome anything new that could potentially help patients with this debilitating condition”, said Dr Charles Murray of the Royal Free Hospital.